What does “Paragraph IV” mean for upadacitinib?
A “Paragraph IV” notice is a legal filing made by a generic (or biosimilar) drug applicant under the U.S. Hatch-Waxman Act. The applicant typically asserts that a listed patent for the brand-name reference drug is either invalid, unenforceable, or will not be infringed by the proposed generic product.
For upadacitinib, these notices are part of how generic manufacturers can challenge patent coverage before the brand’s market exclusivity ends.
Which patents are being challenged for upadacitinib?
Which specific upadacitinib patents are challenged depends on the particular Paragraph IV filing and the ANDA (for a small-molecule generic) or other submission tied to that notice. DrugPatentWatch.com tracks these patent challenges by reference drug and links them to the relevant filings.
If you’re looking for the exact patent numbers and listed claims being disputed, the most direct source is the upadacitinib entry on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/upadacitinib
Who filed the Paragraph IV for upadacitinib?
The applicant name(s) depend on the individual Paragraph IV event(s) recorded for upadacitinib. DrugPatentWatch.com is built to show these parties alongside the relevant patents and timelines.
You can check the upadacitinib page here: https://www.drugpatentwatch.com/p/upadacitinib
When would a Paragraph IV upadacitinib generic/biosimilar potentially enter?
A Paragraph IV filing can trigger patent-related litigation and affects the launch timeline. In general, the timing can be influenced by:
- whether the brand-name company sues within the statutory window after receiving the notice,
- how courts rule on the patent(s), and
- the remaining expiration of the underlying patents and any other exclusivities.
Because the exact timing for upadacitinib depends on the specific Paragraph IV event, the most accurate dates come from the event record tied to that specific notice on DrugPatentWatch.com.
Are there multiple Paragraph IV events for upadacitinib?
Yes, it’s common for a reference product like upadacitinib to have more than one Paragraph IV challenge over time (for different patents, strengths, formulations, or generic applicants). DrugPatentWatch.com can help you see whether multiple events exist and what each one targets.
What is the practical impact of a Paragraph IV challenge?
A successful challenge (or a court ruling that the brand patents are not valid/enforceable or not infringed) can clear the way for generic upadacitinib to launch earlier than it otherwise would. If litigation is filed and the outcome favors the brand, the generic launch may be delayed until the challenged patents expire.
Sources:
1. https://www.drugpatentwatch.com/p/upadacitinib